The Nuclear-Localized AR-V7 Assay Can Be Used as a Predictive Biomarker for CRPC.
In this multi-institutional cohort study, 142 patients with metastatic castration-resistant prostate cancer treated with either taxanes or androgen receptor signaling (ARS) inhibitors were observed for up to 4.3 years. Pretherapy circulating tumor cell status and treatment type were associated with overall survival. Patients with AR-V7–positive circulating tumor cells had superior overall survival with taxanes vs […]
The Nuclear-Localized AR-V7 Assay Can Be Used as a Predictive Biomarker for CRPC. Read More »
